Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

Authors: Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M. and Hickish, T.

Journal: European Journal of Cancer

Volume: 42

Issue: 7

Pages: 827-834

ISSN: 0959-8049

DOI: 10.1016/j.ejca.2005.08.044

Abstract:

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above ({greater than or slanted equal to}70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil) ± mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged {greater than or slanted equal to}70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients {greater than or slanted equal to}70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities. © 2006 Elsevier Ltd. All rights reserved.

Source: Scopus

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.

Authors: Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M. and Hickish, T.

Journal: Eur J Cancer

Volume: 42

Issue: 7

Pages: 827-834

ISSN: 0959-8049

DOI: 10.1016/j.ejca.2005.08.044

Abstract:

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil)+/-mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged > or =70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.

Source: PubMed

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

Authors: Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M. and Hickish, T.

Journal: EUROPEAN JOURNAL OF CANCER

Volume: 42

Issue: 7

Pages: 827-834

eISSN: 1879-0852

ISSN: 0959-8049

DOI: 10.1016/j.ejca.2005.08.044

Source: Web of Science (Lite)

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

Authors: Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M.T.J., Harper, P., Iveson, T.J., Nicolson, M.C. and Hickish, T.F.

Journal: European Journal of Cancer

Volume: 42

Pages: 827-834

ISSN: 0959-8049

DOI: 10.1016/j.ejca.2005.08.044

Abstract:

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil) ± mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged 70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients 70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T68-4J72YT3-1&_user=1682380&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000011378&_version=1&_urlVersion=0&_userid=1682380&md5=d7cc8e04d95c83fc27c842d67fc19fac

Source: Manual

Preferred by: Tamas Hickish

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.

Authors: Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M. and Hickish, T.

Journal: European journal of cancer (Oxford, England : 1990)

Volume: 42

Issue: 7

Pages: 827-834

eISSN: 1879-0852

ISSN: 0959-8049

DOI: 10.1016/j.ejca.2005.08.044

Abstract:

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil)+/-mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged > or =70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.

Source: Europe PubMed Central